Skip to main content
Clinical Trials/NCT00184938
NCT00184938SuspendedNot Applicable

Opioid Induced Acute Preconditioning

Radboud University Medical Center2 sites in 1 country40 target enrollmentStarted: January 2005Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Suspended
Enrollment
40
Locations
2
Primary Endpoint
Percentual difference in Annexin A5 targetting between the experimental and control arm 1 and 4 hours after intravenous injection

Study Overview

Brief Summary

The most powerful protective mechanism against ischemia-reperfusion injury other than rapid reperfusion is ischemic preconditioning. Ischemic preconditioning is defined as the development of tolerance to ischemia-reperfusion injury by a previous short bout of ischemia resulting in a marked reduction in infarct size. This mechanism can be mimicked by several pharmacological substances such as adenosine and morphine.

We, the researchers at Radboud University Nijmegen Medical Centre, have recently developed a method in which we can detect ischemia-reperfusion injury in the human forearm by using Annexin A5 scintigraphy (Rongen et al). With this method we will determine whether opioid receptors are involved in ischemic preconditioning. We expect to find that morphine can mimic ischemic preconditioning and that acute ischemic preconditioning can be blocked with the opioid receptor antagonist naloxon. This study will increase our knowledge about the mechanism of ischemic preconditioning and may also provide leads to exploit this endogenous protective mechanism in a clinical setting.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Masking
Double

Eligibility Criteria

Ages
18 Years to 50 Years (Adult)
Sex
Male
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Healthy male volunteers

Exclusion Criteria

  • Exposition to radiation due to imaging techniques in the previous five years

Outcomes

Primary Outcomes

Percentual difference in Annexin A5 targetting between the experimental and control arm 1 and 4 hours after intravenous injection

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other

Study Sites (2)

Loading locations...

Similar Trials